Genuine Biotech takes third shot at IPO as financial pressures mount
Demand for the company’s core product has long since faded, and sales for the product took an additional hit after the termination of a distribution partnership with Fosun Pharma Key…
Innovative drugs soothe Fosun Pharma from pain of fading Covid vaccine
With China's pandemic controls ending and the WHO adjusting its vaccination recommendations, demand for the company’s comirnaty vaccine is plunging Key takeaways: Fosun Pharma's net profit fell more than 20%…
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Junshi Biosciences is facing business headwinds. Its key cancer drug has not sold as well as competing products and the company has yet to file a marketing application for its…
Genuine Biotech Seeks IPO Booster from New Oral Covid Drug
Company hopes China’s approval of its small molecule oral Covid-19 drug will draw investors to its newly filed listing plan Key Takeaways: Genuine Biotech has filed to list in Hong…
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
-
InnoCare licensing deal flops due to lack of upfront cash
9969.HK688428.SHG
- Intsig scans global financial markets for cash with Hong Kong IPO
